** Shares of Madrigal Pharmaceuticals rise as much as 17.4% to a two-month high of $253.55
** Stock set for its best day since Dec 2022, if gains hold
** Drugmaker's Q3 rev from its sole product, fatty liver drug Rezdiffra, is $62.2 mln, beating Wall Street estimates of $34.2 mln - LSEG
** Fatty liver disease, known as metabolic dysfunction-associated steatohepatitis (MASH), affects around 5% of the U.S. population. The condition was earlier called non-alcoholic steatohepatitis (NASH)
** "This represents a second consecutive quarter of strong launch execution that increases our conviction in the underlying patient/prescriber demand" - Brokerage Leerink Partners
** MDGL has been able to successfully leverage its first-mover advantage and commercial experience to build the NASH market opportunity - Leerink
** In March, Rezdiffra became the first drug for the condition to be approved by the U.S. FDA
** YTD, stock up 8.1%
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.